{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.21","value":"7.19"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"title":"Cycle 02 Day 1, Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.56","value":"6.89"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"title":"Cycle 03 Day 1, Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.66","value":"6.29"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"title":"Cycle 04 Day 1, Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.81","value":"6.53"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"title":"Cycle 05 Day 1, Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.91","value":"6.40"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"title":"Cycle 06 Day 1, Predose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"description":"Plasma concentration of N-desmethyl Apalutamide was reported.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with androgen receptor (AR) expressing locally advanced or recurrent/metastatic salivary gland carcinoma (SGC) received apalutamide 240 milligrams (mg) (4\\*60 mg tablets) orally once daily with or without food in combination with stable regimen of goserelin 3.6 mg administered subcutaneously once per cycle (each cycle is of 28 days) as a gonadotropin-releasing hormone (GnRH) agonist, until disease progression, unacceptable toxicity, death, or end of the study.","id":"OG000","title":"Apalutamide + Goserelin"}],"paramType":"MEAN","populationDescription":"Pharmacokinetics analysis set included all participants with at least 1 apalutamide and/or N-desmethyl apalutamide concentration data after the first study intervention administration. Here, 'N' (number of participants analyzed) specifies all participants who were evaluated for this OM. Here, 'n' (number analyzed) specifies the number of participants evaluated at specified timepoints.","reportingStatus":"POSTED","timeFrame":"Day 1 (predose) of Cycles 2 to 6 (each cycle was of 28 days)","title":"Plasma Concentration of N-desmethyl Apalutamide","type":"SECONDARY","unitOfMeasure":"mcg/mL"}